Hematology AdvisorCurative Potential Seen with Tafasitamab in R/R DLBCL

The phase 2 L-MIND trial presented at the AACR 2023 conference showed that tafasitamab plus lenalidomide and tafasitamab maintenance resulted in durable responses for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The trial treated patients with DLBCL who were not eligible for an autologous stem cell transplant with tafasitamab plus lenalidomide for 12 cycles, followed by tafasitamab alone until disease progression. With a median of 44 months of follow-up for the entire cohort, the objective response rate (ORR) was 57.5%. The ORR was higher among patients who had received only one prior line of therapy at 67.5%, whereas 47.5% of patients who had received multiple prior lines of treatment experienced a response. The complete response rate was 41.3% overall, with the median duration of response (DOR) not reached in all cohorts. The median progression-free survival (PFS) was 11.6 months for the entire cohort, while the median PFS of the cohort with one prior line of therapy was 23.5 months, whereas patients with multiple prior lines of therapy demonstrated a median PFS of 7.6 months. The frequency of treatment-emergent adverse events (TEAEs) decreased over time, and diarrhea and peripheral edema were the most common TEAEs during the initial treatment period with tafasitamab plus lenalidomide.